Innovative Technology Pharmozyme Inc has developed proprietary, contamination-free enzymes and diagnostic kits that address critical needs in molecular biology and infectious disease testing, presenting opportunities to supply advanced reagents and diagnostic solutions to biotech and healthcare labs.

Growing Market Presence With a CE-marked SARS-CoV-2 detection kit and a focus on rapid testing solutions, Pharmozyme is positioned to expand its reach into global in vitro diagnostics markets, especially those seeking high-purity reagents for accurate COVID-19 testing.

Strategic Partnerships As a disruptor in enzyme purity, Pharmozyme can partner with large biotech and pharmaceutical companies focusing on genomic research and diagnostic development to supply specialized reagents that enhance testing accuracy.

Financial Growth Potential Operating with an estimated revenue between one to ten million dollars, Pharmozyme presents an opportunity for scalable growth by targeting expanding biotech and clinical research sectors looking for innovative, contamination-free biotech reagents.

Industry Differentiation Pharmozyme’s unique ability to produce ultra-pure enzymes free from bacterial and animal DNA contamination positions it as a premium supplier for laboratories aiming to improve the reliability of molecular diagnostics and research workflows.